1. No, peer-reviewers do what they can with the limited time and information they are provided.
2. False, The Comment on JAMA Onc does, and the Journal of Neuro-Oncology Editorial both support exactly what I said and more. Both question the validity of the NWBO P3 article.
3. Dr. Bosch is the primary Corresponding Author that managed all the statistical analysis using his hand picked Health Economics consultants -- not experienced clinical trial consultants. All the other listed authors were mostly trial site operators. Only a few were actually producing the manuscript, most just got to review it. Look at the specifications of the authors by contribution.
These are certainly NOT low grade claims -- they challenge the whole conclusion that NWBO has claimed. When regulators get to see all the contested finding, it will be a different review and one that has significant risk of a rejection of the findings because of all the deficiencies that have been identified and now publicly available.
Market Data 
Markets 
AI
